RAPT Therapeutics Files 2025 Proxy Statement
| Field | Detail |
|---|---|
| Company | Rapt Therapeutics, Inc. |
| Form Type | DEF 14A |
| Filed Date | Apr 14, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
RAPT proxy filed for May 29 meeting. Vote on board, pay, and more.
AI Summary
RAPT Therapeutics, Inc. filed its definitive proxy statement on April 14, 2025, for its annual meeting scheduled for May 29, 2025. The company, formerly known as FLX Bio, Inc., is seeking shareholder approval for matters related to its corporate governance and operations. The filing details executive compensation, board nominations, and other shareholder proposals.
Why It Matters
This filing provides shareholders with crucial information to make informed voting decisions on company leadership and strategic direction at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine annual filing (DEF 14A) that outlines standard corporate governance matters and does not contain immediate material financial events.
Key Players & Entities
- RAPT Therapeutics, Inc. (company) — Registrant
- FLX Bio, Inc. (company) — Former company name
- May 29, 2025 (date) — Annual meeting date
- April 14, 2025 (date) — Filing date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with the proxy statement for RAPT Therapeutics, Inc.'s annual meeting of stockholders, detailing information necessary for them to vote on various corporate matters.
When is the RAPT Therapeutics, Inc. annual meeting scheduled to take place?
The annual meeting of stockholders for RAPT Therapeutics, Inc. is scheduled to take place on May 29, 2025.
What was RAPT Therapeutics, Inc. formerly known as?
RAPT Therapeutics, Inc. was formerly known as FLX Bio, Inc., with a date of name change on May 4, 2016.
What is the filing date of this proxy statement?
This definitive proxy statement was filed with the SEC on April 14, 2025.
What is the primary business of RAPT Therapeutics, Inc. according to the filing?
RAPT Therapeutics, Inc. is classified under the Standard Industrial Classification code 2834, which pertains to Pharmaceutical Preparations.
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 14, 2025 regarding RAPT Therapeutics, Inc..